December 13, 2021 -- Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing.
The study will evaluate the cost-effectiveness of implementing blood-based CGP in the public healthcare system. The study, titled "IMPRESS-Norway," is designed to match previously approved cancer medicines with other tumors, depending on their molecular profile, to drive a precision medicine approach to cancer therapy selection. The CGP analysis will be done using Illumina's dynamic read analysis for genomics software.
Less-invasive CGP testing of blood samples could potentially replace tissue sampling, substantially increasing the number of patients who are able to have their tumors profiled and who can then be included in clinical trials for cancer therapy selection, according to the firm.
For the study, the CGP testing of blood and tissue samples will be carried out across a network of pathology departments that span Norwegian hospitals.